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Abstract 
In spite of having received considerable interest as a potential anticancer agent over the past two decades, 
curcumin has not been developed into a sturdy drug candidate yet, mainly due to the challenges imposed by 
its rapidly metabolizable structure, leading to bioavailability and stability issues, and its aspecific activity. To 
circumvent these obstacles, chemical modification of the parent scaffold has been shown to involve an eligible 
approach for the construction of curcuminoids with improved properties. This review article provides a 
compilation of curcumin modifications and the effect thereof on the anticancer activity displayed by the 
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Curcumin, a natural product extracted from the rhizomes of the turmeric plant Curcuma longa, has been 
commonly used as a food additive and a traditional medicine in South Asia. In addition, curcumin has been 
explored pharmacologically by many researchers, driven by the shedload of biological potential associated 
with this compound. The promising prospects of curcumin-based molecules have indeed attracted notable 
attention, especially in the field of oncology. However, curcuminoids exhibit propitious effects on 
inflammation, ageing, diabetes, and cardiovascular diseases, among other potential applications as well.1-3 
Despite this broad therapeutic window, most of the curcumin research is linked to anticancer activity. 
Malignant disorders represent a major health challenge accounting for more than 8 million deaths per year 
and therefore new therapeutic opportunities in that context are highly desirable. Curcumin-based studies 
within that framework include curcumin-mediated suppression of cell proliferation, reduction of tumor load 
and induction of apoptosis in various cancers, both in vitro and in vivo.4 The anticancer activity of curcumin is 
effective through several pathways such as an induction of p53-dependent apoptosis pathways in different 
cancer cells (colon, breast, bladder), and stimulation of both p53-dependent and p53-independent G2/M 
phase arrest has also been shown to exert inhibitory effects on cyclooxygenase COX-2 and proto-oncogene 
cyclin D1, mediated through the transcription factor NF-κB and hence the restriction of tumor cell growth in 
colorectal cancer.5-8 The growth of malignant tumors has been observed to be restricted upon these 
mechanisms along with an inclusion of pro-apoptotic, antiproliferative, antioxidant and anti-inflammatory 
mechanisms.9,10 However, the lack of understanding of the mode of action coupled with other issues such as a 
low bioavailability leading to a poor absorption in the body still remains a huge obstacle in the development of 
curcumin-derived pharmaceuticals. Indeed, although curcumin has been amply shown to inhibit cancer cell 
proliferation, it is rapidly metabolized and systemically eliminated from the human body, and it suffers from 
chemical degradation in aqueous solutions.11,12 In contrast to other polyphenols, the degradation of curcumin 
is not related to its phenolic groups but is rather induced by hydrolysis of the labile β-diketo moiety. 
Unfortunately, these drawbacks imply a serious concern and hamper potential applications of curcumin in 
health care. In addition to bioavailability and stability issues, the mode of action of curcuminoids remains 
poorly understood; hence, they are often considered to be pan-assay interference compounds (PAINS) 
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showing rather unspecific activity across a range of assays.13 But it has been recently demonstrated that 
curcumin is able to block Kaposi’s sarcoma associated herpesvirus replication and inhibits the pathogenic 
processes of cell invasion and angiogenesis predicting a potential application in treatment of viral infection 
and virus-related cancer and also suggesting that curcumin is not a PAINS but an inhibitor to APE1 redox 
function that affects many genes and pathways.14 Nevertheless, it might be possible to circumvent problems 
associated with low bioavailability, low stability and non-specific activity to a great extent through structural 
modifications of the basic curcumin framework. Curcumin contains a β-diketo moiety, two phenolic groups 
and two olefinic entities delivering a broad diversity of options for chemical modification of the curcumin 
scaffold. The curcumin framework has been utilized frequently for a variety of straightforward 
transformations, mainly focused on the synthesis of pyrazoles and isoxazoles,15-17 but the dearth of the 
investigation of an extensive range of transformations still provides opportunities for further exploration. For 
example, a recent study revealed improved water solubility, antioxidant effects and anti-proliferative activities 
upon replacement of the curcumin β-diketo moiety with a β-enaminone group.18,19 In addition to enaminone 
production, other synthetic transformations, such as replacement of the aromatic benzene rings by 
heteroaromatic scaffolds and simultaneous modification of the olefinic and diketo moieties, were also 
addressed as a part of this review to examine rather unapprised innovative classes of curcuminoids. 
Despite many recent realizations in curcuminoid chemistry and biology, current contributions remain 
insufficient for the development of curcumin-based drugs, which has been acknowledged in a J. Med. Chem. 
Perspective, calling upon the curcumin chemistry community to move towards more out-of-the-box 
approaches.20 The present review article has the intention to outline the state-of-the-art and to provide 
anchor points to guide future synthetic endeavors in this field of research. 
 
 
2. Chemical Structure and Biological Interest of Curcuminoids 
 
Curcumin (diferuloylmethane) is a polyphenolic compound that can be isolated from different sources, e.g., 
the roots of the plants Curcuma longa, Curcuma zedoaria, and Curcuma aromati. The major curcuminoids 
present in turmeric are bisdemethoxycurcumin 2, demethoxycurcumin 3 and the later identified 
cyclocurcumin 4.21 The main components of commercially available curcumin samples are approximately 77% 
curcumin 1, 17% demethoxycurcumin (DMC), and 3% bisdemethoxycurcumin (BDMC) (Figure 1).22,23 
Curcuminoids are a class of natural compounds found in turmeric responsible for imparting a yellow color to 
it, but are not essentially limited to diferuloylmethane (curcumin), demethoxycurcumin and 
bisdemethoxycurcumin. Turmeric has initially been put forward as a food spice used as an essential ingredient 
of curries and as a part of Asian cuisine, primarily for the flavor and the color, and has also been used to cure a 
variety of inflammation-related health problems by Asians since long.24,25 The scope of the research to seek 
new potential anticancer agents stems from the toxicity, virtually inefficiency, and expense of the existing 
ones, thus rendering them far out of reach for a large number of population groups. Curcumin has been 
shown to have a potentially strong therapeutic profile against a variety of cancers and a promising ability to 
suppress transformation, proliferation, and metastasis of tumors based on research in the past few decades 
with no considerably muddling side effects often associated with traditional medications like nausea, 
vomiting, diarrhea or even liver failure.22,26,27 Curcumin has also been noted for its rather high tolerance levels 
with doses of 12 grams per day being both safe and efficacious.28 To that end, its use as a regular dietary 
supplement in some parts of Asia might therefore be one of the contributing factors for the lower incidence of 
cancer in those regions compared to the western world.29 
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Figure 1. Chemical structure of curcuminoids 1-4. 
 
Chemically speaking, curcumin is a bis-α, β-unsaturated β-diketone that exhibits keto-enol tautomerism, with 
the enol tautomer as the predominant form in solution based on NMR studies at pH 3-9.30 The planarity of the 
enol form allows for intramolecular hydrogen bonding (which leads to a more stable structure). However, the 
compound is more stable in acidic conditions and rapidly degrades at either natural or alkaline pH (Figure 
2).11,20,31 There have been attempts to improve the stability of 1 through synthetic manipulations, including 
encapsulation strategies,32,33 removal or protection of oxidation sites,34 and derivatization of the diketone 
moiety.35,36 
An example of the effect of structural modifications of the curcumin scaffold comprises of the significantly 
different antioxidant, antitumor, and anti-inflammatory activities of compounds 1-3 through only the 
introduction of a methoxy substituent. Till date, there has been no clear correlation between the 
physicochemical and molecular properties of the three curcuminoids and their biological activities, but there 
are reports that provide clues to map the groups responsible for a given biological activity within the 
curcuminoid series. Most studies suggest that curcumin 1 is the best radical scavenger and antioxidant among 
the three, followed by compounds 3 and 2 in decreasing order of potential, which is explicable in terms of O-
methoxy substitutions: intramolecular hydrogen bonding between the phenolic hydroxy and methoxy groups 
(in 1 and 3) influences the O–H bond energy, subsequently easing the H-atom abstraction by free radicals, and 
thus the absence of this methoxy group in the compound 2 renders it as the weakest radical scavenger.37 
Despite great advances in curcuminoid research, there are still several challenges to be addressed, such as 
understanding the mode of action of curcumin and improving its low bioavailability due to its poor solubility 
and fast metabolism. Curcumin has also been observed (via HPLC-MS) to degrade into vanillin, ferulic acid, and 
feruloylmethane under different conditions.11,38 Thus, for the foreseeable future, further research shall most 
likely focus on overcoming these disadvantages through encapsulations/nanoparticles,39-62 combination 
effects with piperine to enhance the bioactivity/bioavailability63-73 and – of particular interest to this overview 
– structural modifications.7,22,23,74,75 
In this literature review, the general synthetic route towards curcumin and optimization thereof is discussed, 
since that approach forms the basis for further derivatization. An overview of the oncological applications of 
curcumin(oids) has been dispensed, followed by a discussion of the structural modifications to the curcumin 
scaffold that have been performed as a strategy to improve its pharmacokinetic profile. 
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Figure 2. Possible major degradation pathways of curcumin 1. 
 
 
3. General Synthetic Routes to Curcumin and its Analogs 
 
The general synthetic strategy towards curcumin and its derivatives involves the condensation of substituted 
benzaldehydes with acetylacetone (Figure 3).76,77 The synthesis of curcumin 1 under variable reaction 
conditions such as solvent systems, complexing agents, temperature, time and amount of H2O scavenger, has 
been studied in detail in order to achieve an optimized process. For the synthesis of curcumin 1, acetylacetone 
and 4-hydroxy-3-methoxybenzaldehyde (vanillin) were used in a theoretically stoichiometric ratio (1:2). Boric 
oxide was used as a complexing agent to protect the C3 of acetylacetone from Knoevenagel condensation. 
Solvent selection was also an important factor in the optimization process to obtain the appropriate solubility 
for the reactants, intermediates and products. Various solvents were screened, including dimethylformamide 
(DMF), ethyl acetate (EtOAc), 1,4-dioxane, acetonitrile (MeCN) and toluene (Table 1). Furthermore, it is critical 
to select a basic catalyst that ideally only deprotonates the methyl groups of acetylacetone (in all chosen 
solvents), because a stronger base can also deprotonate the phenolic OH group, which might result in the 
deactivation of vanillin and thus prevent the condensation reaction. The base n-butylamine (n-BuNH2) was 
identified as the most appropriate catalyst. Catalyst loading was performed slowly up to 40% (volume) of 
acetylacetone.76,78 
The reaction was carried out under anhydrous conditions by using high purity solvents, as water molecules 
could bind to the diketone complex (i.e., complex of acetylacetone and boron, Figure 3) and reduce the yield. 
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However, water is also produced when the diketone complex and curcumin are formed. Therefore, tributyl 
borate (n-BuO)3B was incorporated as a water scavenger in order to bind to H2O molecules produced during 
the reaction. Varying ratios of (n-BuO)3B were tested to find the optimal amount.
76-78Another parameter 
influencing the reaction between the diketone complex and vanillin is the temperature. Below 40°C, the 
reaction rate was too slow to get a workable yield, so higher temperature conditions had to be procured. In 
that respect, the reaction conditions were altered by varying the solvents at different temperatures (Table 1), 
with n-butylamine as a catalyst and (n-BuO)3B as a water scavenger (if any). First the reaction between 
acetylacetone and vanillin with a molar ratio of 1:2, respectively, was carried out at 60°C in DMF. The 
complexing agent (B2O3) was added at an equivalent molar ratio to acetylacetone without any water 
scavenger. After 12 h, only a 6% yield was obtained. No significant improvement in yield was observed upon 
repetition with a water scavenger.78 
Subsequently, other solvents were utilized with varying reaction parameters, including amount of water 
scavenger (n-BuO)3B and catalyst (n-BuNH2 or other bases), time and temperature. In ethyl acetate, an 
increased amount of (n-BuO)3B did improve the yield significantly from 21% to 43%. In the presence of 
acetonitrile and dioxane, almost identical yields were obtained. Using toluene as a solvent resulted in very low 
yields, even at higher temperatures. Ethyl acetate (EtOAc) was found to give the most significant improvement 
in yield due to better solubility of the reactants, intermediates and products, delivering the highest yield (89%) 





Figure 3. General synthetic route to curcumin 1. 
 






Temp. (°C) Time (h) Yield (%) 
DMF - - 60 12 6 
DMF (n-BuO)3B 2:1 80 12 15 
EtOAc - - 60 4 21 
EtOAc (n-BuO)3B 2:1 60 4 43 
EtOAc (n-BuO)3B 2:1 80 4 89 
Dioxane (n-BuO)3B 2:1 60 12 20 
MeCN (n-BuO)3B 2:1 60 12 18 
Toluene (n-BuO)3B 2:1 60 12 3 
Toluene (n-BuO)3B 2:1 80 12 6 
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4. Curcumin against Cancer 
 
Cancer involves the dysregulation of multiple cellular pathways that normally regulate cell proliferation. The 
annual global incidence of cancer is expected to increase from 14.1 million new cases in 2012, with 8.2 million 
deaths to nearly 25 million new cases in 2032.79 Most drugs currently available for the treatment of cancer 
have limited potential because they are either very toxic, highly inefficient, or too expensive for the majority 
to afford. Treatments without these disadvantages are constantly being sought for, with curcumin presenting 
itself as a potential scaffold for future studies. To an advantage, curcumin has been consumed as a dietary 
supplement for centuries and is considered to be pharmacologically safe.25 
Accumulating evidence suggests that curcumin has a diverse range of molecular targets, which supports the 
notion that it influences numerous biochemical and molecular cascades. Among its molecular targets are 
transcription factors, growth factors and their receptors, cytokines, enzymes, and genes regulating cell 
proliferation and apoptosis. Extensive investigation suggests that curcumin has therapeutic potential in the 
treatment of various disorders (Scheme 1) as it is known to reduce blood cholesterol,80-85 prevent low-density 
lipoprotein oxidation,86-88 inhibit platelet aggregation,89,90 suppress thrombosis91,92 and myocardial 
infarction,93-96 suppress symptoms associated with type II diabetes,97-104 rheumatoid arthritis,105-109 multiple 
sclerosis110 and Alzheimer’s disease,111-115 inhibits HIV replication,116-124 enhance wound healing,125-130 protect 
against liver injury,131-138 prevent cataract formation,139-141 protect from pulmonary toxicity and fibrosis, has 
therapeutic effects in leishmaniasis,142-144 and has anti-atherosclerotic activity.145-147 Most importantly, there is 
extensive literature suggesting that curcumin has potential in the prevention and treatment of various 
cancers, including colorectal cancer,148,149 pancreatic cancer,150 breast cancer,70,151 prostate cancer,152 multiple 
myeloma,151 lung cancer and oral cancer.151 The ability of curcumin to target multiple pathways makes it an 
extremely potent anticancer agent. Despite having multiple pharmacological effects and being safe in phase-I 
clinical evaluations (even at high doses of 12 g/day),28 curcumin has poor in vivo bioavailability, as 
demonstrated by its low serum levels and limited tissue distribution.12,153-155 It has been found that curcumin 
can be mostly metabolized in liver (hepatocyte cells) and intestine,156 through both conjugation and reduction 
pathways in humans and rodents. Curcumin given orally undergoes conjugation, resulting in curcumin 
glucuronide and sulfates on hydroxy positions on the curcumin scaffold (Figure 5). Curcumin administered 
intraperitoneally or systemically undergoes reduction to generate tetrahydrocurcumin (THC, 5), 
hexahydrocurcumin (HHC, 6) and octahydrocurcumin (OHC, 7) (Figure 4 and Scheme 2).157,158 It has been 
suggested by a study conducted for evaluation of tetrahydrocurcumin 5 as an anticancer agent relative to 
curcumin and a standard anticancer drug 5-fluorouracil (5-FU) employing three ESCC cell lines TE-1, TE-8 and 
KY-5 that further investigation of tetrahydrocurcumin in combination with standard treatments should be 
considered particularly for chemo-resistant ESCC because of the observed significant suppression of TE-1 cell 
proliferation with 5-FU in combination with tetrahydrocurcumin in contrast to no significant repression with 5-
FU alone at the same dosage.159 Tetrahydrocurcumin 5 has also been gaining research interest because of a 
better water solubility, anti-oxidative activity and chemical stability than curcumin. The revelation from many 
in vitro and in vivo studies that it brings into play regarding anti-cancer effects through diverse mechanisms 
such as xenobiotic detoxification, metastasis, proliferation, inflammation, oxidative stress and programmed 
cell death gives an idea that its utility is yet to be extensively evaluated as only a few oral bioavailability and 
pharmacokinetic studies have been performed so far.160 
Recently a nanoparticle-based administration of curcumin resulted in a 27-fold increase of blood levels in 
humans compared to that of curcumin powder indicating a promising therapeutic strategy for tackling 
bioavailability issues.161 Moreover, the comparisons between orally administered and intravenously (IV) 
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administered routes have been illustrated in Scheme 2 in order to provide a clear understanding of the 





Figure 4. Metabolization of curcumin through reduction pathways provides analogs 5-7. 
 
Although the multicomponent nature of curcumin is well documented, it is not always clear as to which 
structures exist in a particular preparation. Herein the term curcumin will often be used interchangeably with 
curcuminoids unless a distinction is specifically made. Many studies with in vitro experiments use synthetic, 
pure curcumin while most in vivo studies and clinical trials use a mixture of curcuminoids.20 In many scientific 
and medicinal circles, the extensive reported effects of curcumin have marked it as an imminent breakthrough 
therapy for complex diseases that are thought to require potent but nonselective remedies. Unfortunately, 
the uncritical enthusiasm for its potential benefits often disregards its dark side (poor bioavailability and fast 
metabolism).162 This eagerness could lead to an overly-optimistic interpretation of results, and consequently, 
compounds could be misidentified as a hit for drug development. As a matter of fact, neither curcumin nor its 
known analogs appear to possess the properties required for good drug candidates, i.e., chemical stability, 
high water solubility, potency, selectivity, high bioavailability, broad tissue distribution and stable metabolism. 
In that respect, the key challenge in curcumin research involves the elimination of these undesirable 
properties through structural modification and careful biological evaluation of novel types of curcuminoids, 
hopefully obtaining good candidates for an anticancer drug in the process. 
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Figure 5. Phase I and phase II (glucuronidation) metabolism of curcumin via UGT enzyme.163,164 
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Scheme 1. General illustration of the biological effects of curcumin. 
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Scheme 2. An illustration of potential delivery systems (oral administration vs IV routes)156 to enhance 
curcumin bioavailability (F) via either formulations41,43,59,61,62 or piperine66,69,71 and metabolic 




5. Structural Modification  
 
The rapid degradation of curcumin brings about many challenges while investigating its biological influences 
(both in vitro and in vivo), which could be overcome through chemical modification strategies. Curcumin is a 
symmetrical diferuloylmethane, consisting of a methoxy group and a hydroxy group on its aromatic rings, a 
heptadiene with two Michael acceptors, and a β-diketone moiety. These groups are often modified in the 
hope of creating structural homologs with improved bioactivity and/or bioavailability compared to the original 
structure. Generally, an aldehyde (usually vanillin) and acetylacetone form the building blocks of curcumin. A 
wide variety of curcumin analogs can be synthesized by using different aldehydes as well as acetylacetone 
derivatives,119,174-192 including C3-substituted acetylacetone or acetylcycloalkanones (Figure 6).193,194 
A structure-activity relationship (SAR) study of symmetrical curcuminoids showed that the feruloyl (aromatic) 
moiety plays a critical role in various biological functions. As previously mentioned, curcumin is stable at an 
acidic pH, and its instability at a pH above 6.5 (i.e. physiological conditions) is most likely due to the active 
methylene group and the β-diketone moiety. This suggests that the deletion or modification of the β-diketone 
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moiety may contribute to the enhancement of stability of curcuminoids. In this literature study, we focus on 
several curcumin analogs prepared both synthetically and semi-synthetically, mostly containing changes in 
aromatic ring substitutions or transformations of the β-diketone moiety (Scheme 3).  
The synthesis and anti-tumor assessment of the series of phosphorylated, etherified and esterified forms of 
curcumin  against human breast cancer MCF-7, hepatocellular carcinoma Hep-G2 and cervical carcinoma HeLa 
cells showed a better antitumor cell line growth activities against HeLa cells in comparison with those of 
curcumin itself.195 Another simple prodrug report has been put on the table which takes into account the 
generation of nanoparticles of curcumin in situ allowing it to perform as an anticancer and anti-inflammatory 
agent reproducibly; diphosphorylated curcumin which in this approach essentially is a precursor for curcumin 
and a substrate of alkaline phosphatase (ALP) exhibited selective inhibition of cancer cells that overexpressed 




Scheme 3. Possible structural modifications to create curcumin analogs. 
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Figure 6. Curcuminoid analogs 8-25. 
 
5.1. Changes in aromatic ring substitutions 
The antioxidant activity of curcumin 1 is not only due to its phenolic groups but also the ortho-methoxy 
functionality. Thus, it is anticipated that modifications of the substituents on the aromatic moiety will affect 
antioxidant activity. As mentioned earlier, the ortho-methoxy group can form an intramolecular hydrogen 
bond with the phenolic hydrogen, facilitating H-atom abstraction from the ortho-methoxy phenols. The 
scavenging activity significantly decreased in the order THC (18.7 µM, 5) > HHC (21.6 µM, 6) = OHC (23.6 µM, 
7) > Trolox (31.1 µM) ≥ curcumin (35.1 µM, 1) > DMC (53.4 µM, 3) >> BDMC (> 200 µM, 2).37 However, an 
increased number of hydroxy groups on the aromatic moiety (e.g. polyhydroxy-curcuminoid 26, Scheme 4) 
showed interesting antioxidant properties.197 Non-phenolic analogs 27-31 were either less active or inactive as 
antioxidants. It has been suggested that the steric crowding at ortho positions in compounds 32-34 (Scheme 4) 
contributes to a facile transfer of hydrogen atoms by stabilizing the phenoxy radical and preventing the 
phenolic group from forming a hydrogen bond with the medium, but when the R2 and R4 groups were 
replaced with bulkier tert-butyl groups (C(Me)3, 35), antioxidant activity was reduced significantly due to the 
absence of a hydroxy group compared to 26.198,199 
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Compound R1 R2 R3 R4 R5 
26 H OH OH OH H 
27 H OMe OMe H H 
28 H OMe OMe OMe H 
29 OMe OMe OMe H H 
30 H OMe OMe H OMe 
31 H H OMe H H 
32 H OMe OH OMe H 
33 H OCH2Me OH H H 
34 H Me OH Me H 
35 H C(Me)3 OCOMe C(Me)3 H 
 
Scheme 4. Chemical structures of curcuminoid analogs with aromatic ring substitutions 26-35. 
 
5.2. Changes in β-diketone moiety  
5.2.1 Pyrazole and isoxazole analogs. The enol form of curcumin in solution was found to be responsible for 
its rapid degradation, and hence, to inflate the firmness of the structure, a number of analogs has been 
synthesized in which the diketone moiety was replaced by an isoxazole or pyrazole group. Interestingly, 
compounds 36 and 37 showed better free radical scavenging activity than curcumin with an IC50(µM) value for 
inhibition of proliferation of the A549 cells upon treatment with 37 being 3.70±0.16 compared to the value of 
11.0±0.59 for curcumin 1 in RAW 264.7 cells (Figure 7).200 Synthesis, characterization and testing of in vitro 
anticancer activity of a novel series of curcumin analogs to explore potential therapeutics established 
compound 38, which exhibited the best activity among several compounds tested and may be transformed 
further into a potential therapeutic.200 A number of click diarylpentane curcuminoids and their pyrazole 
derivatives has been synthesized, and this class of compounds validates as novel types of antimiotic agents, 
recognizing the pyrazole adduct 39 as a promising lead.200 Curcumin analogs of benzyloxime and the isoxazole 
and pyrazole substitutes demonstrated amplification in the antitumor activity both in the parental and in MDR 
MCF-7 cells.200  
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Figure 7. Structures of synthesized curcumin isoxazoles, pyrazoles and their analogs 36-43. 
 
Isoxazole and pyrazole derivatives were shown to be less prone to nucleophilic benzyl mercaptan addition 
than curcumin itself and demonstrated a better cell growth inhibition and pro-apoptotic effect in liver cancer 
HA22T/VGH cells as well as other tumor cells.200  A series of new pyrazole derivatives of THC, a major 
metabolite of curcumin, has shown to exhibit excellent anticancer activity against MCF-7 cell lines with good 
IC50 values.
200 4-Bromophenyl derivative 40 at the pyrazole moiety was the most effective and inhibited the 
growth of all three tested cell lines with IC50 values of 8.0 µM (A549), 9.8 µM (HeLa) and 5.8 µM (MCF-7).
200 
Other pyrazole and triazole curcumin analogs have been synthesized and shown to exhibit activity at the 
micromolar range against head and neck cancer, among which compounds 42 and 43 demonstrated potent 
cytotoxicity values against HNSCC cell lines. Interestingly, compounds 41 and 42 appeared to have a 
pronounced effect on pSTAT3 phosphorylation with compound 42 being the first reported click chemistry 
curcumin analog showing good cytotoxic activity. Disruption of pFAK and pAKT phosphorylation signaling is 
shown with compound 43.200 A number of pyrazole derivatives of penta-1,4-dien-3-one compounds containing 
a substituted pyrazole were synthesized and some of those showed significant antiproliferative activity against 
HepG2 cell lines with an IC50 value of 0.10-5.05 µM compared to a value of 16.20 µM for Sorafenib.
200 
Pyrazole 45 and isoxazole 47 analogs of curcumin 1 were produced with different substituents on the active 
methylene group. For the synthesis of pyrazole derivatives 45, diketo derivatives 44 were prepared and 
reacted in an acid-catalyzed condensation reaction with 1.2 equivalents of hydrazine hydrochloride 
(NH2NH2HCl) in absolute ethanol under reflux for forty hours (Scheme 5).
201 Likewise, isoxazole derivatives 47 
were prepared from compounds 46 using hydroxylamine hydrochloride (NH2OHHCl) (Scheme 6). Reported 
yields were generally high, ranging from 58% to 90%, with only compound 45g having a very low yield of 15%. 
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Scheme 5. Knorr pyrazole synthesis of pyrazole curcuminoids 45. 
 
In a study on the investigation of curcumin analogs as antimalarial agents, some new pyrazole derivatives 
(48a-e) containing an N-phenyl group were prepared (Scheme 7).202 For their synthesis, curcumin 1 was 
dissolved in glacial acetic acid and reacted with 1.25 equivalents of the appropriate hydrazine under reflux. 
Phenylhydrazine, 4-fluorophenylhydrazine, 3-nitrophenylhydrazine, 2,4-dichlorophenylhydrazine and 4-
methoxyphenylhydrazine were used to produce the corresponding compounds 48a-e, respectively. In contrast 
to previous reactions, low to good yields (35-71%, Scheme 6) were obtained after a reaction time of 8 
hours.202 Additionally, analogs 45a and 47a were also evaluated for antimalarial activity against Plasmodium 




Scheme 6. Synthesis of isoxazole curcuminoids via Paal-Knorr chemistry 47. 
 
These molecules were prepared using a similar procedure as mentioned previously. The study reported good 
antimalarial activity exerted by compounds 45a and 48c, with respective IC50 values of 0.48 ± 0.04 μM and 
0.87 ± 0.07 μM, which is a higher potency compared to curcumin 1 (3.25 ± 0.6 µM).202 
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Scheme 8. Synthesis of pyrazole and isoxazole curcuminoids 49 via microwave irradiation. 
 
Modifications to the conventional synthesis procedure are also possible; for instance, three of the previously 
discussed isoxazole and pyrazole analogs have been synthesized with the assistance of microwave irradiation 
(Scheme 8).203 Compounds 49a-c correspond to 48a, 45a, and 47a. They were produced by reacting an 
equivalent amount of curcumin 1 and hydrazine (phenylhydrazine, hydrazine hydrate, and hydroxylamine 
hydrochloride, respectively) in 2 mL of glacial acetic acid for two minutes while being subjected to microwave 
irradiation. In a modified procedure, three more isoxazole/pyrazole analogs (49a-c) of curcumin 1 were 
prepared using microwave irradiation.203 This short procedure resulted in very high yields (84-87%). Compared 
to the duration of conventional reactions which could last from 8 to 40 hours, microwave irradiation seems to 
hold a remarkable potential in curcumin synthesis.201-203  
Isoxazole analogs of curcumin exhibited antiproliferative and cell death effects in MCF-7R comparable to those 
achieved in MCF-7 and cause minor changes in NF-ĸB or STAT3 activation.200 4,4’-(1E,1’E)-2,2’-[1-(3-
chlorophenyl)-1H-pyrazole-3,5-diyl]bis(ethene-2,1-diyl) bis(2-methoxyphenol) showed a high degree of 
cytotoxicity and cell proliferation inhibition against cancer cells and can be selected for further in vitro and in 
vivo investigations.200 Isoxazole analogs of curcumin exhibited significantly improved in vitro drug-like 
properties including solubility, metabolic stability, cell permeability and lack of nonspecific cytotoxicity when 
compared with curcumin.200 
5.2.2. β-enaminones. Also β-enaminone analogs (50a-e) have been prepared in low yields (25-35%) by adding 
the appropriate primary amine to a mixture of curcumin 1 and acetic acid (Scheme 9). Any water formed 
during the reaction was removed via the Dean-Stark setup.204 Dioxime analogs 51a-b were prepared by adding 
a solution of curcumin 1 and two equivalents of O-methyl or O-benzylhydroxylamine hydrochloride in 25% 
water-ethanol (1:3) to a solution of potassium carbonate in water (Scheme 9).204 The mixture was then heated 
under reflux for 25 minutes. Compounds 50a and 50b were obtained in 40% and 34% yield, respectively. 
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Scheme 10. Synthesis of pyrimidine-substituted curcumin analogs 55. 
 
For the synthesis of compounds 55, two equivalents of 3,4-dimethoxybenzaldehyde 52 were reacted with 4,6-
dimethyl-2-hydroxypyrimidine hydrochloride 53 in a solvent mixture of toluene and ethanol (1:3) with HCl as 
the catalyst. The obtained product 54 was then combined with diisopropylethylamine (DIPEA) in an excess of 
phosphoryl chloride (POCl3) at reflux temperature. Here, the hydroxy group of 54 is substituted by a chlorine 
(not shown), and this intermediate can in turn react with a selected primary amine in EtOH to form the desired 
products 55 (Scheme 10).205 These compounds have been shown to be active and promote apoptosis against 
colon cancer (HTC116 cell line), which was consistent with the multiple functions of EGFR signaling pathways. 
Sulfonamide-containing curcuminoids 57 and 58 can be synthesized from imination with sulfanilamides in 
ethanol (Scheme 11).206 When acetic acid is added as the catalyst, compound 57 can react with sulfanilamide 
again and result in 58. These curcumins showed interesting antibacterial properties (against Staphylococcus 
aureus, Bacillus cereus, Salmonella typhi, Pseudomonas aeruginosa, Escherichia coli: MIC = 20-80 μM) and 
antifungal activities (against Aspergillus niger, Aspergillus flavus, Curvularia lunata, Trichoderma viride: MIC = 
40-80 μM), as well as moderate cytotoxicity (IC50 values = 25-50 μM/mL against HeLa, HepG2, QG-56 and 
HCT116 cell lines). 
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Scheme 11. Synthesis of new derivatives of curcumin containing sulfonamides 57 and 58. 
 
5.2.3. Monocarbonyl analogs of Curcumin (MACs). To contend with research on traditional curcumin, the 
chemical class of curcumin monocarbonyl analogs has evolved bearing biological properties similar or superior 
to curcumin itself, furnishing a 10-20 fold potency gain for a number of cancer cell lines and cellular proteins 
and better pharmacokinetic profiles in mice, as well as higher tumor regression in cancer xenografts in vivo 
than curcumin.207 As the instability of curcumin stems from the methylene group and β-diketone moiety, the 
absence of the β-diketone moiety in monocarbonyl analogs may help enhance its stability. These analogs can 
be symmetrical, non-symmetrical or cyclic. An example class is made up by replacing the central 1,3-diketo 
structure by a piperidone skeleton 59 and 60 (Figure 8). This class is characterized by a better stability and 
easier synthesis compared to that of curcumin 1.208,209 
Compound 59 has been shown to have good anti-inflammatory activity.188,189 A more remarkable analog is 
compound 60, better known as EF24,210-214 which has been reported to work more effectively against several 
cancer cell lines than the regularly used chemotherapeutic drug Cisplatin®. In the field of anti-angiogenesis, 
the potency of compound 60 approaches the level of the drug TNP-470, an analog of Fumagillin.208,215 Further 
research on piperidone analogs furnished compound 65 that was even more powerful, synthesized by reaction 
of 2-chlorobenzaldehyde 62 and 4-piperidone hydrochloride 63 in glacial acetic acid (Scheme 12).216 The 
reagents undergo a Claisen-Schmidt condensation, and compound 64 is formed. Finally, 64 is reacted with 




Figure 8. Monocarbonyl curcuminoids 59-61.163,164,204,207 
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Scheme 12. Synthetic approach towards 3,5-bis(2-chlorobenzylidene)-4-piperidones 64 and synthesis of N-acyl 
derivatives of 3,5-bis(2-chlorobenzylidene)-4-piperidone 65. 
 
MAC curcumin analogs are often assessed in phenotypic assays such as proliferation and angiogenesis by 
investigators in cancer studies. One of the MACs, EF31 (61, Figure 8) has shown to be able to block 22 of 50 
cancer-related kinases by a recent modest kinase screen.207 In addition to other techniques, glycosylation is 
also known to significantly alter the properties of small molecules and therefore concerns a frequently applied 
modification of drug-like compounds. For example, glycosylation can enhance water solubility and the stability 
and/or bioactivity of target structures. In that respect, the glycosylation of curcumin has been explored 
intensively in the literature, e.g. culminating in efficient biocatalytic methodologies to efficiently produce 
curcumin (di)glucoside.217 
A series of symmetric piperidones 66-89 (Figures 9 and 10) has been synthesized to evaluate cytotoxic effects 
using murine P388 and L1210 cells as well as human Molt4/C8 and CEM T lymphocytes, amongst which the 
average value for the N-acrolyl analogs 75-81 being 1.8 µM for the four cell lines while the N-unsubstituted 
compounds 82-88  furnished a higher average of 44 µM, for which the electronic parameters were deemed 




Figure 9. Structures of anticancer MACs 66-74. 
 
Another series of MACs 89-97 (Figure 10) was produced and tested for anti-proliferation and anti-angiogenic 
activity. Analogs 60 (EF24), 91, 92 and 93 showed cytotoxicity better than cisplatin being effective in anti-
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proliferation assays as well as efficacious in anti-angiogenesis assays.207  The data suggest that (i) the 
symmetrical α,β-unsaturated ketone moiety installed shows a superior anticancer activity compared to the β-
diketone structure of curcumin; (ii) ortho-substitution on aromatic rings (91-93, Figure 10) increases the 
activity compared to the meta- or para-substitutions (95, 96, Figure 10) being a little less active; and (iii) a 
heteroatom in the cyclic ketone (92, 93 and 97, Figure 10) generally results in improved anticancer and anti-
angiogenic activity. Compound 90 was further investigated and found to decrease cell viability of lung cancer 
cells, and an interesting observation was made in context of its anti-hypoxia inducible factor(HIF)-1 activity 
compared to curcumin: while curcumin inhibited HIF-1α gene transcription, 90 inhibited HIF-1α post-
transcriptionally, and also curcumin brings out microtubule stabilization in cells, whereas 90 has no effect.207  
Symmetrical 1,5-diarylpentanediones 98-102 (Figure 11) were produced, synthesized and tested against cell 
growth of colon cancer cells. The compound 99 was determined to exhibit a four times higher potency than 
curcumin with an IC50 value of 2 µM compared to a value of 8 µM for curcumin.
207 Compounds 103-106 were 
evaluated by means of anti-proliferation and anti-angiogenic assays. Anti-angiogenic activity was 
demonstrated by considerable reduction of micro vessel density in peritoneum wall sections in Ehrlich ascites 
tumor mouse models. The two aromatic regions were interpreted to be critical for potential drug-protein 
interactions from the study.207  
Among the aromatic enone and dienone analogs 107-115 showing cell proliferation upon being screened in an 
in vitro anti-angiogenic assay, 111 and 114 were found to be particularly potent, indicating the importance of 
heterocyclic substitution. The same group subsequently came up with generated derivatives with variation in 
the substitution pattern of benzene rings or fusion characteristics, systems 116-119 being the most important, 
which are structurally tetralones introducing rigidity in the molecule. The 2-napthyl analog 117 exhibited the 
best anti-angiogenic activity, 85% at 1 µg/mL in the sequence 117>118>116>119.207  
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Figure 10. Structures of anticancer MACs 75-97. 
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Figure 12. Structures of anticancer MACs 120-133. 
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A series of non-symmetrical MAC chalcones was conceived by coupling substituted phenyl amides with the 
terminal curcumin styrene unit with m-OMe and p-OH substitution, giving rise to structures 120-133 (Figure 
12). The particular importance of non-symmetrical phenyl alkyl amides coupled with heteroaromatic moieties 
is suggested by the potent anti-antigiogenic activity of 129, 130, 132 and 133 due to in vitro growth inhibition 
of human umbilical vein endothelial cells (HUVEC).207 
A series of highly polar MACs 134-149 (Figure 13) was synthesized by replacement of the keto-enol 
functionality by a substituted piperidone, and the compounds 141-149 were found to be significantly more 
potent than the control agent Melphalan in inhibition of leukemia and colon cancer cell lines in human Molt 
4/C8 cells and CEM T-lymphocytes, but compounds 134-140 lost activity. The change in potential can be 




Figure 13. Structures of anticancer MACs 134-149. 
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Figure 14. Structures of anticancer MACs 150-162. 
 
A collection of largely acyclic MACs 150-162 (Figure 14) has been synthesized, and their antitumor activity was 
tested by blocking the proliferation of prostate and breast cancer cells, out of which compound 158 bearing 
three methoxy groups was found particularly active with an IC50  within the µM
 range.207 The compounds 163-
175 (Figure 15) were reported to be cytotoxic to the human colon cancer cell line HCT-116.207 This study 
highlighted the structural motifs for bis(arylmethylidene)acetone and 3-oxo-1,4-pentadiene and the dress of 
substitution being important for maintaining high levels of cell cytotoxicity. Structurally similar compounds 
176 and 177 were presented to induce tumor cell apoptosis by activating the stress mechanism of 
endoplasmic reticulum by another group and have been reported to be under preclinical study for non-small 
cell lung cancer.207 Compounds 178 and 179 also inhibited phosphorylation of STAT3 in breast and prostate 
cancer cells. Another series of novel 3,5-bis(arylidene)-4-piperidone based symmetrical MACs was screened 
for their potential anticancer activity, with compounds 180 and 181 showing inhibition against many human 
cell lines. 
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Figure 16. Structures of anticancer MACs 182-193. 
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More recently, compound 182 (Figure 16) has been determined to elicit an anti-angiogenic activity by 
suppressing the downstream protein kinase activation of vascular endothelial growth factor (VEGF) via 
decreasing phosphorylation of AKT and p38. Compound 183 was also reported to display an antitumor effect 
in the MTT cell proliferation assay using a H460 non-small cell lung cancer cell line.207 A Guangzhou-New 
Jersey collaboration reported an in vitro activity for two series of analogs, thiopyran-4-ones 184-187 and the 
benzyl piperidones 188-190 (Figure 16). The thiopyranones were shown to deliver suppressive IC50 values < 1 
µM upon testing in an MTT proliferation assay against prostate PC-3, HT-29 colon and Panc-1 cancer cell lines. 
In a parallel study with benzyl piperidones 188-190, PC-3, pancreas BxPC-2, HT-29, and H1299 lung cancer cell 
lines were probed with growth inhibition, MTT and trypan blue exclusion assays and the compounds were 
found to be active with IC50 values < 2 µM.
207 Structures 191-193 (as nitrogen-containing heterocyclic 
derivatives) were reported to furnish anti-prostate cytotoxicity IC50 values of 50-390 nM and no toxicity 




Figure 17. Structures of anticancer MACs 194-195. 
 
Finally, two piperidines 194 and 195 (Figure 17) displayed inhibition of the ĸB activation complemented by 
substantial toxicity towards MBA-MB-231, MDA-MB-468 and SkBr3 breast cancer cell lines; models for triple 
cancer. Against the MBA-MB-231 cell line, the EC50 values are submicromolar at 0.8 and 0.3, respectively, 
while they cause apoptosis in 40%-45% of the SKBr3 and MDA-MB-231 cells.207  
 
5.3. Modification of both the aromatic rings and the β-diketone moiety 
A part of the recent research in our lab has intensively focussed on the synthesis and evaluation of novel 
curcuminoids and their evaluation as anticancer agents. In view of the problem of low bioavailability being 
associated partly with the labile β-diketo structure, thirteen N-alkyl enaminones 196-208 (and bis-acetylated 
curcumin 209) were synthesized starting from curcumin 1 and bisdemethoxycurcumin 2 using montmorillonite 
K10 clay and microwave irradiation (Scheme 13), and a number of nitrogen derivatives showed promising 
effects upon characterization in terms of solubility, chemical antioxidant properties and in screening assays for 
cell toxicity, growth and oxidative stress using CHO-K1, EA.hy926, HT-29 and Caco-2 cell lines. It was concluded 
that the cellular responses are strongly increased by N-analogs, and all the compounds appeared to induce no 
toxicity effects on differentiated intestinal cells.18 
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Scheme 13. Synthesis of β-enaminones 196-208 and bis-acetylated curcumin 209.  
 
New analogs 210-217 (Scheme 14) were then prepared in continuation of this work using more polar amines 
with an aim of improving water solubility without altering the biological activity of the resulting curcuminoids, 
again starting from curcumin 1 and bisdemethoxycurcumin 2 and employing different solvents to minimize the 
formation of side products 218-220. The resulting β-enaminones displayed activities better than or 
comparable to curcumin, and water solubility was also found to be improved significantly.19 
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Scheme 15. Synthesis of β-enaminones 222-232.  
 
Another set of pyridine-, indole- and pyrrole-based curcumin analogs 222-232 was synthesized with the 
objective of addressing the bioavailability and improvement of biological activity of curcumin (Scheme 15).218 
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All of these symmetrical aza-heteroaromatic curcuminoids showed better water solubility profiles in 
comparison to curcumin and bisdemethoxycurcumin. 
A set of non-symmetrical curcuminoids 235-252 (Figure 18) containing both a phenolic group and an 
azaheteroaromatic scaffold was further prepared in continuation of this work in order to combine good 
solubility, antioxidant potential and cytotoxic properties in a single molecule (Scheme 16).219 252 was 
synthesized to compare its activity with 247 and 251, which both contain a thiophen-2-yl moiety. All the 
derivatives displayed a better water solubility than curcumin and higher IC50 values for non-carcinogenic cells 
than carcinogenic cell lines, implying that they might be less harmful toward healthy cells. The study 
concluded that the preservation of the 4-hydroxy-3-methoxyphenyl moiety may provide interesting properties 




Scheme 16. Synthesis of β-enaminones 235-251.  
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Figure 18. Structures of curcuminoids 235-252. 
 
Another small set of monocarbonyl analogs of curcumin 255-260 was also synthesized (Scheme 17) and 
evaluated for cytotoxicity. In particular, bis-3-methoxy-4-hydroxy- and bis-4-methoxyphenyl-substituted 
monocarbonyls were synthesized and transformed into three-dimensional N-acetylpyrazoline derivatives.220 
Preliminary cytotoxic evaluation revealed significant effects for 4-hydroxy (pyrazoline) monocarbonyl 
curcuminoid 257, and non-phenolic variants displayed rather poor activity. 
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Scheme 17. Synthesis of β-enaminones 255-260.  
 
Deviating from the classical flat curcuminoid framework, an unexplored modification has been investigated 
recently, in which novel out-of-plane 1,4-thiazepane-based curcuminoids 264-287 (Figure 19) were prepared 
(Scheme 18), and the impact of this modification was examined on their biological activity.221 Thiazepane 
analogs 264-278 were generated from starting materials curcumin 1 and bisdemethoxycurcumin 2 or the 
pyridin-3-yl analog of curcumin, compounds 281-284 were prepared via O-acetylation from derivatives of 
series 264-278, and unprecedented thiazepine-pyrazoline curcuminoids 285 and 286 were constructed via an 
extension of enone structural modification of analogs 264 and 272. Arylmethylidene-substituted 
cyclohexenones 279 and 280, based on substrates indol-3-yl and pyrrol-2-yl curcuminoids, were selectively 
produced using ethanol as the solvent. Furthermore, fluorophenyl-containing cyclohexanone 287 was 
synthesized for the first time by changing n-butylamine to di-isopropylamine, which stimulated the attack of a 
second molecule of acetylacetone. The synthesized derivatives 266-268, 272-273, 277-278, 279, 285 and 287 
displayed a better antiproliferative activity compared to the parent compounds 1 and 2, and in some cases a 
better activity than Doxorubicin, an established anticancer drug. The cell protectivity tests were conducted 
with derivatives 264-265, 269-270, 275-276 and a better cytoprotection than curcumin 1 and a comparable 
cytoprotective capacity as that of ascorbic acid and Trolox was observed. Because of their three-dimensional 
architecture, generally culminating in a better druglikeness, and their promising cytotoxic properties, these 
thiazepane-based curcuminoids can be considered as an innovative scaffold for further elaborations en route 
to the development of curcumin-based anticancer drugs. 
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Scheme 18. Synthesis of curcuminoids 264-287.  
DOI: https://doi.org/10.24820/ark.5550190.p011.314 Page 257  ©AUTHOR(S) 
 
 




Arkivoc 2020, vii, 257-305    Theppawong, A. et al. 
 
 Page 291  ©AUTHOR(S) 
Conclusions 
 
Despite its celebrated pharmacological profile, limitations associated with the natural product curcumin, such 
as structural instability, low solubility and aspecific activity, have incited medicinal chemists to pursue the 
construction of new derivatives. In this short literature overview, the synthesis and biological assessment of 
selected curcumin analogs is discussed, some of them demonstrating superior activities as compared to the 
parent curcumin scaffold. It is clear that this field has witnessed major efforts related to pyrazole and isoxazole 
curcuminoid synthesis, culminating in interesting new structures in terms of stability, solubility and/or activity, 
although it is expected that more innovative approaches will be required to also address the problem of non-
specific biological interactions. In particular, the search for curcuminoids bearing a higher sp3 fraction, 
exemplified by the recently discovered thiazepane curcuminoid framework, could provide a breath of fresh air 
in this field by developing stable three-dimensional structures with a better druglike profile, without 
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